The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
Official Title: Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female Brazilian, Taiwanese and Thai Subjects Who Had Received Control Vaccine in Study 580299/008
Study ID: NCT00849381
Brief Summary: This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
Detailed Description:
Minimum Age: 26 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil
GSK Investigational Site, Campinas, , Brazil
GSK Investigational Site, Curitiba, , Brazil
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Bangkok, , Thailand
GSK Investigational Site, Bangkok, , Thailand
GSK Investigational Site, Bangkok, , Thailand
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR